Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells by Parisi, Silvia et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 

 
 The Rockefeller University Press, 0021-9525/2003/10/303/12 $8.00
The Journal of Cell Biology, Volume 163, Number 2, October 27, 2003 303–314
http://www.jcb.org/cgi/doi/10.1083/jcb.200303010
 
JCB
 
Article
 
303
 
Nodal-dependent Cripto signaling promotes 
cardiomyogenesis and redirects the neural fate 
of embryonic stem cells
 
Silvia Parisi,
 
1
 
 Daniela D’Andrea,
 
1
 
 Carmine T. Lago,
 
1
 
 Eileen D. Adamson,
 
2
 
 M. Graziella Persico,
 
1
 
 
and Gabriella Minchiotti
 
1
 
1
 
Institute of Genetics and Biophysics, “Adriano Buzzati-Traverso,” Consiglio Nazionale delle Ricerche, 80131 Naples, Italy
 
2
 
Cancer Research Center, The Burnham Institute, La Jolla, CA 92037
 
he molecular mechanisms controlling inductive events
leading to the speciﬁcation and terminal differentiation
of cardiomyocytes are still largely unknown. We
have investigated the role of Cripto, an EGF-CFC factor, in
the earliest stages of cardiomyogenesis. We ﬁnd that both
the timing of initiation and the duration of Cripto signaling
are crucial for priming differentiation of embryonic stem
(ES) cells into cardiomyocytes, indicating that Cripto acts
early to determine the cardiac fate. Furthermore, we show
that failure to activate Cripto signaling in this early window
T
 
of time results in a direct conversion of ES cells into a
neural fate. Moreover, the induction of Cripto activates
the Smad2 pathway, and overexpression of activated
forms of type I receptor ActRIB compensates for the lack of
Cripto signaling in promoting cardiomyogenesis. Finally,
we show that Nodal antagonists inhibit Cripto-regulated
cardiomyocyte induction and differentiation in ES cells. All
together our ﬁndings provide evidence for a novel role of
the Nodal/Cripto/Alk4 pathway in this process.
 
Introduction
 
Specification of vertebrate cardiac mesoderm is the first
developmental step leading to heart formation occurring
concurrently with gastrulation (Fishman and Chien, 1997).
The formation of a vertebrate heart from an amorphous field
of precursor cells takes place through multiple developmental
steps, such as determination of the cardiac field in the
mesoderm, differentiation of cardiac precursor cells into
cardiomyocytes, and heart morphogenesis (Olson and Sri-
vastava, 1996). No other early differentiation event is more
vital for survival; it must occur in a short time to provide a
working circulation system for the rapidly growing embryo
(Rosenthal and Xavier-Neto, 2000). Precursor cells, destined
for the heart, originate in the lateral epiblast and migrate
through the primitive streak to emerge as cardiogenic meso-
derm already specified as distinct cardiac lineages. Bilateral
fields of cardiogenic mesoderm continue to migrate rostrally
and eventually join at their anterior boundaries to form the
cardiac crescent, where they commit to cardiac fate (Ro-
senthal and Xavier-Neto, 2000). The understanding of early
cardiogenesis is of particular interest as cardiomyocyte loss
in mammals is largely irreversible and frequently underlies
the diminished cardiac function associated with heart diseases
(Gepstein, 2002). Recently, some of the secreted factors
required for cardiogenesis have been identified (McFadden
and Olson, 2002). Members of the bone morphogenetic
protein (BMP), Wnt, and EGF-CFC families have been
implicated in vertebrate myocardial development. Zebrafish
with mutations in the BMP2 homologue gene 
 
swirl
 
 and
one-eyed pinhead (the zebrafish member of the vertebrate
EGF-CFC family) exhibit severe defects in myocardial
differentiation and reduced expression of two early markers
of the myocardial precursors Nkx2.5 and GATA5 (Reiter et
al., 2001). Results obtained in 
 
Xenopus
 
 and chick indicate that
BMP signals from the endoderm induce cardiomyocyte fate,
whereas Wnt-mediated signals from the underlying neural
tube and notochord suppress cardiomyocyte specification
(Schultheiss et al., 1997; Marvin et al., 2001; Tzahor and
Lassar, 2001). It has been hypothesized that cardiac muscle
cell specification is likely to depend on the location and
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duration of signals governing more general developmental
decisions in the early embryo (Rosenthal and Xavier-Neto,
2000). In this scenario, the mouse 
 
cripto
 
 gene, the founding
member of the EGF-CFC family, appeared to have a crucial
role. In mouse embryos, the 
 
cripto
 
 expression profile is asso-
ciated with the developing heart structures and is detected
first in the precardiac mesoderm (Dono et al., 1993). Later
on, at 8.5 dpc, 
 
cripto
 
 expression is found in the ventriculus,
before being specifically restricted, at 9.5 dpc, to the truncus
arteriosus of the developing heart (Dono et al., 1993). Nota-
bly, mouse 
 
cripto
 
 mutants exhibit defects in myocardial de-
velopment, as evidenced by the absence of expression of ter-
minal myocardial differentiation genes such as 
 
 
 
-myosin
heavy chain (
 
 
 
MHC) and myosin light chain 2v (MLC2v)
(Ding et al., 1998; Xu et al., 1999). Accordingly, by using
embryoid bodies (EBs) derived from Cripto
 
 
 
/
 
 
 
 ES cells, it
has been shown that 
 
cripto
 
 is essential for cardiomyocyte in-
duction and differentiation (Xu et al., 1998). However, how
 
cripto
 
 functions to regulate cardiogenesis is still unknown.
To study this process, we took advantage of embryonic stem
(ES) cells, which have been widely used as a model system of
cardiogenesis, proven to be a powerful tool to study early
events of cardiac induction (Doetschman et al., 1993;
Monzen et al., 2001, 2002; Boheler et al., 2002). To create a
system in which we could manipulate Cripto activity, we de-
veloped an assay in which recombinant Cripto protein re-
stored cardiomyocyte differentiation in Cripto
 
 
 
/
 
 
 
 ES cells.
This approach allowed us to define the dynamics of Cripto
signaling required for differentiation of cardiac precursor
cells. We showed that Cripto is required in a precise mo-
ment during differentiation, after which it fails to specify the
cardiac lineage. Moreover, we found that the absence of
Cripto signaling in this early acting window of time resulted
in a direct conversion of Cripto
 
 
 
/
 
 
 
 EB–derived cells into a
neural fate. This observation suggests that Cripto inhibits
mammalian neuralization and supports the hypothesis that a
default model for neural specification is operating in ES
cells. Furthermore, we show that Cripto protein activates
the Smad2 pathway during cardiomyocyte induction and,
moreover, that overexpression of an activated form of type I
receptor ActRIB restored the ability of Cripto
 
 
 
/
 
 
 
 ES cells to
differentiate into cardiomyocytes. Taken together, our re-
sults indicate that Cripto participates in heart development,
regulating early events that lead to cardiac specification, and
highlight a novel role for the Nodal/Cripto/Alk4 pathway in
cardiomyogenesis.
 
Results
 
Secreted Cripto retains its ability to rescue 
cardiomyocyte differentiation
 
Previous data on cultured ES cells lacking 
 
cripto
 
 have re-
vealed an essential role of 
 
cripto
 
 for contractile cardiomyo-
cyte formation. Cripto
 
 
 
/
 
 
 
 ES cells selectively lose the ability
to form beating cardiomyocytes, a process that can be res-
cued by expression of Cripto (Xu et al., 1998). As Cripto is a
GPI-anchored membrane protein, we first determined if a
secreted form of Cripto could restore cardiomyocyte differ-
entiation in Cripto
 
 
 
/
 
 
 
 ES cells (Fig. 1). To this end, we
overexpressed a secreted derivative of Cripto, which lacks the
hydrophobic COOH terminus region required for mem-
brane anchorage (Minchiotti et al., 2000), in Cripto
 
 
 
/
 
 
 
 ES
cells and compared its activity to that of wild-type (wt)
Cripto (Fig. 2 A). A pooled population of cells selected for
resistance to puromycin were examined for the number of
EBs containing beating areas, from day 8 to 12 of the in
vitro differentiation assay. Spontaneous rhythmic contractile
myocytes were observed in Cripto
 
 
 
/
 
 
 
 ES cells expressing ei-
ther the membrane-anchored or the secreted Cripto protein
(Fig. 2 B). Moreover, similar results were obtained by ex-
pressing a secreted Cripto protein that lacks the NH
 
2
 
 termi-
nus region (EGF-CFC; Fig. 2, A and B), thus indicating
that not only membrane anchorage is dispensable for activ-
ity, but that the EGF-CFC domain alone is sufficient for
Cripto activity in the cardiogenic induction. Previous data
have shown that a refolded synthetic Cripto peptide con-
taining the EGF-like domain had mitogenic and branching
activity for mammary cell lines (Salomon et al., 1999). We
thus went on to define whether the Cripto EGF-like domain
alone was able to induce cardiogenesis similar to the EGF-
CFC peptide. Two 
 
cripto
 
 cDNA deletion derivatives encod-
ing either the EGF-like domain retaining the NH
 
2
 
 terminus
region (EGF long) or just the EGF domain (EGF short; Fig.
2 A) were generated. No beating areas were observed in EBs
derived from Cripto
 
 
 
/
 
 
 
 ES cells expressing either EGF long
or EGF short peptide (Fig. 2 B), thus indicating that both
EGF and CFC domains of Cripto are essential for cardio-
genic induction. Western blot analysis showed that the EGF
long and EGF short peptides were produced and secreted as
efficiently as EGF-CFC (Fig. 2 C and not depicted), thus
demonstrating that their inability to rescue the mutant phe-
Figure 1. Schematic representation of the experimental protocol 
used for ES cell differentiation into cardiomyocytes (adapted from 
Maltsev et al., 1993).T
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notype was not due to a difference in protein expression
level. To support the morphological data observed, we ex-
amined the expression levels of the cardiac-specific 
 
 
 
MHC
and MLC2v, two major contractile proteins of cardiomyo-
cytes. As expected, expression of both the 
 
 
 
MHC and
MLC2v genes was induced in wt ES cells but not in
Cripto
 
 
 
/
 
 
 
 cells from day 7 of in vitro differentiation (Fig. 2
D). Importantly, the expression pattern of 
 
 
 
MHC and
MLC2v genes in wt ES cells was reproduced in Cripto
 
 
 
/
 
 
 
cells expressing either wt Cripto or the secreted derivative,
but not in cells expressing either EGF long or EGF short
peptides (Fig. 2 E).
 
Timing and duration of Cripto activity in 
cardiomyocyte differentiation
 
To gain further insight into the functional role of Cripto in
cardiogenic induction and differentiation, we first examined
the timing of Cripto expression during ES cell differentia-
tion. Western blot analysis performed with anti-Cripto anti-
bodies on lysates from both wt and Cripto
 
 
 
/
 
 
 
 ES cells re-
vealed that Cripto was detectable as early as day 0 and
peaked in expression by day 4 in wt EBs (Fig. 3). Impor-
tantly, the transient nature of Cripto accumulation sug-
gested that its activity might be required at a defined step in
cardiomyocyte differentiation. The time window of Cripto
action could not be adequately investigated by means of
transfection assays. Therefore, to directly address this issue, a
recombinant soluble Cripto protein was used in which the
hydrophobic COOH terminus was replaced by a 6xHis
epitope (Cripto-His; Minchiotti et al., 2001). Based on our
observation that secreted Cripto protein is able to promote
cardiogenesis when expressed in the Cripto
 
 
 
/
 
 
 
 ES cells (Fig.
2 B), experiments were performed where Cripto signal-
ing was reconstituted by addition of recombinant secreted
Cripto protein directly to the cells (Fig. 4). Addition of
Cripto during the 0–2-d interval effectively restored the dif-
Figure 2. Functional dissection of Cripto. (A) Schematic representation of cripto cDNA derivatives. S.P., signal peptide. (B) Determination 
of minimal domains required for Cripto activity in cardiomyocyte differentiation. Either wt or deleted cripto mutant derivatives were transfected 
into Cripto
 /  ES cells; empty vector was used as control. The percentage of EBs with rhythmically contracting areas detectable by light 
microscopy was scored on day 8 to 12. Data are representative of at least two independent experiments. (C) Western blot analysis of conditioned 
media from 293EBNA cells transfected with cripto cDNA deletion derivatives. Cells were cotransfected with Plgf expression vector as an 
internal control (see Materials and methods). Lane 1, EGF-CFC; lane 2, EGF long; lane 3, vector. The molecular mass of protein standards is 
indicated (kD). (D) Expression of cardiac-specific genes MLC2v and  MHC during in vitro differentiation of either wt or Cripto
 /  ES cells. 
RT-PCR was performed on RNA extracted from either undifferentiated ES cells or EBs throughout a differentiation period of 10 d (days 2–10). 
HPRT gene expression was analyzed as an internal control. (E) RNA expression levels of MLC2v and cardiac  MHC genes during in vitro 
differentiation of Cripto
 /  ES cells overexpressing either wt or cripto deletion mutants. RNA was harvested at days 5, 7, and 10 of the 
differentiation protocol and subjected to RT-PCR. Empty vector was used as a negative control. HPRT gene expression was analyzed as an 
internal control. The results are representative of two independent differentiation programs.T
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Figure 4. Dynamics of Cripto signaling in cardiomyocyte differentiation. (A) Definition 
of the temporal activity of Cripto. Percentage of Cripto
 /  EBs containing beating areas 
after addition of recombinant Cripto protein. 10  g/ml of soluble Cripto protein was 
added to EBs at 24-h intervals starting from time 0 of the in vitro differentiation assay 
(scheme in Fig. 1). The number of EBs containing beating areas was scored from day 8 
to 12 of in vitro differentiation. (B) Dose-dependent activity of Cripto protein. 2-d-old 
Cripto
 /  EBs were treated with increasing amounts of recombinant soluble Cripto protein 
for 24 h and then cultured for the remaining days. Appearance of beating areas was 
scored from day 8 to 12 of the in vitro differentiation. (C) Duration of Cripto signaling. 
2-d-old Cripto
 /  EBs were treated with 10  g/ml of recombinant soluble Cripto protein 
for different lengths of time, 1, 12, 24, and 72 h. EBs were then washed to remove the 
protein and cultured for the remaining days. Cells were examined for cardiac differentiation 
as described above. In all cases, two independent Cripto
 /  ES clones (DE7 and DE14) 
were used. Data are representative of at least two independent experiments.
 
ferentiation ability of Cripto
 
 
 
/
 
 
 
 ES cells. Addition at later
time points resulted in dramatically reduced cardiomyocyte
differentiation (Fig. 4 A). Comparable results were obtained
with two independent Cripto
 
 
 
/
 
 
 
 ES clones (DE7 and
DE14; Xu et al., 1998), thus excluding any phenotype dif-
ference due to clonal variation (Fig. 4 A). All together, these
data indicated that stimulation in trans with soluble Cripto
protein was fully efficient in promoting cardiomyocyte in-
duction and differentiation and, more interestingly, defined
exactly when Cripto activity was required to promote speci-
fication of the cardiac lineage. Furthermore, to define the
optimal concentration of Cripto required to promote car-
diogenesis, increasing amounts of purified recombinant
Cripto protein were added directly to the culture medium of
2-d-old Cripto
 
 
 
/
 
 
 
 EBs from either DE7 or DE14 cell lines
for 24 h (Fig. 4 B). Increasing amounts of recombinant
Cripto resulted in enhanced differentiation efficiency (Fig. 4
B), thus indicating that Cripto-mediated cardiogenic induc-
tion was dose dependent.
Having shown that the timing and dose of Cripto signal-
ing activation were crucial to promote cardiomyocyte induc-
tion and differentiation, we thus went on to define whether
the duration of Cripto signaling was crucial for its biological
response. 2-d-old EBs from DE7 or DE14 Cripto
 
 
 
/
 
 
 
 ES cells
were treated with 10 
 
 
 
g/ml of recombinant Cripto for vari-
ous lengths of time, washed to remove unbound Cripto, and
then cultured for the remaining days. An effective Cripto re-
sponse required a minimum induction of 24 h, while shorter
inductions showed markedly reduced activity (Fig. 4 C).
Taken together, our data demonstrated that the amount,
timing, and duration of Cripto signaling were all crucial fac-
tors to achieve cardiogenic induction and differentiation.
 
Direct conversion of Cripto
 
 
 
/
 
 
 
 EB–derived cells into 
a neural fate
 
Our observation that initiation of Cripto signaling in an
early acting window of time is crucial for priming differ-
entiation of ES cells to cardiac fate prompted us to gain
further insight into the functional role of Cripto at an
early phase of ES cell differentiation. Interestingly, when
Cripto
 
 
 
/
 
 
 
 EBs were plated onto an adhesive substrate, a
population of cells with a neuron-like morphology was ob-
served that produced a network surrounding the aggre-
gates. This characteristic morphology was never observed
either in wt EBs or in Cripto
 
 
 
/
 
 
 
 EBs treated with effective
doses of Cripto protein. To confirm that those cells were
indeed neurons, immunofluorescence analysis was per-
formed on both wt and Cripto
 
 
 
/
 
 
 
 EBs, by using antibodies
that recognize the neuron-specific form of class 
 
 
 
III tubu-
Figure 3. Cripto expression profile during the in vitro differentiation 
of ES cells. Total lysates of either undifferentiated ES cells or EBs at 
different days of differentiation (2–7 d), derived from either RI (wt) or 
DE7 (Cripto
 / ) ES cells, were collected in lysis buffer and analyzed by 
Western blot using a polyclonal anti-Cripto antiserum (Minchiotti 
et al., 2000). Data were normalized to the expression level of Porin.T
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lin. These antibodies stained clusters of cells in Cripto
 
 
 
/
 
 
 
EBs, revealing the presence of a dense network of neurons
(Fig. 5 A). Neurons were detected in 71% of Cripto
 
 
 
/
 
 
 
EBs, whereas 
 
 
 
III-tubulin–positive cells were never de-
tected in both wt EBs and rescued Cripto
 
 
 
/
 
 
 
 EBs that, on
the contrary, showed extensive areas of MF-20–positive
cardiomyocytes (Fig. 5 A). To gain insight into this issue,
we used our controlled differentiation assay to modulate
Cripto signaling and to eventually score EB-derived cells
for either cardiomyocyte or neuron differentiation, by us-
ing morphological criteria as well as immunofluorescence
analysis. Addition of Cripto protein during the 0–2-d
interval rescued, as expected, the cardiac phenotype of
Cripto
 
 
 
/
 
 
 
 ES cells (Fig. 5 B), but also resulted in a dra-
matic inhibition of neural differentiation (Fig. 5 B). Con-
versely, addition of recombinant Cripto at later time
points (i.e., 3–6-d interval) resulted in progressive impair-
ment of cardiac differentiation (see previous paragraph and
Fig. 5 B) and, at the same time, increased competence of
the EB-derived cells to acquire a neural phenotype, result-
ing in close to 70% of Cripto
 
 
 
/
 
 
 
 EBs that show extensive
areas of 
 
 
 
III-tubulin–positive cells. All together our results
support the hypothesis that Cripto signaling represses neu-
ral differentiation in ES cells and, moreover, show that the
restricted time window of Cripto signaling required to
achieve proper terminal cardiac differentiation of Cripto
 
 
 
/
 
 
 
ES cells correlates with the competence window for those
cells to become committed to a neuronal phenotype.
 
Cripto activates a Smad2 pathway associated with 
cardiomyocyte differentiation
 
Findings in mice, 
 
Xenopus
 
, and zebrafish point to a strong
functional link between the EGF-CFC proteins and TGF
 
 
 
ligand Nodal (Shen and Schier, 2000; Adamson et al.,
2002). Accordingly, recent studies have shown that Cripto
can associate with type I receptor ActRIB (Alk4) and can
form a complex together with Nodal and type II receptor
ActRIIB (Reissmann et al., 2001; Yeo and Whitman, 2001;
Bianco et al., 2002; Yan et al., 2002). Activation of Smad
proteins by phosphorylation is a universal signal transduc-
tion event following activation of Alk receptors. To ask
whether Cripto activates the Smad2 pathway during cardio-
myocyte induction and differentiation, 2-d-old Cripto
 
 
 
/
 
 
 
EBs were starved in low serum for 3 h and then stimulated
with recombinant soluble Cripto protein for 30, 60, or 120
min. Western blot analysis revealed that phosphorylation of
Smad2 significantly increased after treatment with recombi-
nant Cripto (Fig. 6). Smad2 phosphorylation was detectable
already after 30-min treatment, persisting at comparable lev-
els even after prolonged exposure to Cripto protein. An anti-
Smad2/3 antibody applied to the same blot was used to nor-
malize for total amount of protein (Fig. 6). In vitro studies
on mammary cell lines have suggested that Cripto is in-
volved in the Ras/Raf/MEK/MAPK pathway (Salomon et
al., 1999). When we looked for activation of the MAP ki-
nase ERK by using an anti–phospho-ERK antibody, recom-
binant Cripto was unable to activate MAP kinase (unpub-
Figure 5. Cripto promotes cardiomyocyte differentiation and inhibits neural differentiation of ES cells according to the timing of exposure. 
(A) Cardiomyocyte versus neuronal differentiation of Cripto
 /  EBs as revealed by indirect immunofluorescence. 2-d-old Cripto
 /  EBs, derived 
from DE7 cell line, were either left untreated (a and c) or treated for 24 h with 10  g/ml of recombinant Cripto protein (b and d). On day 12 
of in vitro differentiation, expression of either sarcomeric myosin or  III-tubulin was revealed by immunofluorescence using anti–MF-20 (red, 
a and b) or  III-tubulin (green, c and d) antibodies, respectively. Data are representative of at least two independent experiments. Comparable 
results were obtained with Cripto
 /  DE14 ES cell line. (B) Cardiomyocyte versus neuronal differentiation of Cripto
 /  EB–derived cells depends 
on the timing of exposure to Cripto. Percentage of Cripto
 /  EBs stained for  III-tubulin (red plot) or MF-20 (blue plot) after addition of 
recombinant Cripto protein at different time points. 10  g/ml of recombinant Cripto protein was added to EBs at 24-h intervals starting from 
time 0 of the in vitro differentiation assay. On day 12 of in vitro differentiation, EBs were stained for either  III-tubulin or MF-20 antibodies. 
Data are representative of two independent experiments.T
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lished data); thus indicating that the Smad2 pathway was
selectively activated during cardiomyocyte induction and
differentiation induced by Cripto.
To our knowledge, no data are available on the expression
profile of all components of the Alk4/ActRIIB/Nodal com-
plex during the differentiation of ES cells; thus, we first mea-
sured by RT-PCR the expression of Nodal, Alk4, and Ac-
tRIIB in EBs derived from both wt and Cripto
 /  ES cells.
Nodal, Alk4, and ActRIIB were expressed in all analyzed
stages (Fig. 7 A). If Cripto signaling in cardiomyocyte differ-
entiation acts via the Alk4 receptor, overexpression of a
constitutively active type I receptor would be expected to
compensate for the lack of Cripto signaling in promoting car-
diomyocyte differentiation. We overexpressed in Cripto
 / 
ES cells the wt or constitutively activated form (ca) of either
human HA-tagged Alk4 or its zebrafish counterpart Taram-A
(Renucci et al., 1996). Type I receptor serine/threonine ki-
nases can be activated in a ligand- and type II receptor–inde-
pendent manner by replacing an acidic residue for a specific
threonine within the juxtamembrane region of the intracellu-
lar domain, a segment known to be involved in kinase regula-
tion (Wieser et al., 1995). Overexpression of either Alk4 ca or
Taram-A ca partially restored the ability of Cripto
 /  ES cells
to differentiate into cardiomyocytes (Table I). On the con-
trary, overexpression of the wt receptors, either Taram-A or
Alk4, had no significant activity despite their similar expres-
sion levels (Fig. 7 B). Furthermore, addition of recombinant
Cripto to Alk4 ca–expressing cells restores cardiomyocyte dif-
ferentiation close to controls (Table II). In accordance with
the morphological data, expression of the  MHC gene was
only detected in Cripto
 /  ES cells expressing the activated
form of the receptors (Fig. 7 C). Altogether, our results pro-
Figure 6. Activation of Smad2 in Cripto
 /  cell aggregates treated 
with recombinant Cripto protein. 2-d-old Cripto
 /  EBs were serum 
starved for 3 h and then treated with 10  g/ml of recombinant Cripto 
protein for 30’, 60’, or 120’ or left untreated, as indicated. Smad2 
activation was detected by Western blot analysis using anti–phospho-
Smad2 antibody. Levels of total Smad2 were also compared.
Figure 7. Expression profile of Nodal, Alk4, and ActRIIB during 
cardiomyocyte differentiation and their effects on cardiac induction. 
(A) RNA expression levels of Nodal, Alk4, and ActRIIB genes during 
in vitro differentiation of ES cells. RT-PCR analysis was performed 
on RNA extracted from either undifferentiated ES or EBs (either wt 
or Cripto
 / ) throughout a differentiation period of 10 d (days 2–10). 
HPRT gene was used as an internal control. (B) Western blot analysis 
of total lysates from 293EBNA cells transfected with either wt or ca 
form of HA-tagged human Alk4. Cells were cotransfected with Jun-HA 
expression vector as an internal control. A monoclonal anti-HA 
antibody was used to detect protein levels. (C) RNA expression 
profile of the  MHC gene during differentiation of Cripto
 /  ES cells 
(days 5, 7, and 10) overexpressing wt and activated forms of either 
Alk4 or Taram-A. HPRT gene was used as an internal control.
Table I. Percentage of beating EBs from Cripto
 /  ES cells 
transfected with either wt or ca form of human Alk4 or 
zebrafish Taram-A receptors
Cells Construct EBs scored % of beating EBs
DE7 None 70 0
DE7 Cripto wt 50 96.6
DE7 Alk4 wt 76 0
DE7 Alk4 ca 50 16.0
DE7 Taram-A wt 55 0
DE7 Taram-A ca 64 45.0
DE7 Empty vector 56 0
DE14 None 80 0
DE14 Cripto wt 54 94.4
DE14 Taram-A wt 50 1.9
DE14 Taram-A ca 51 62.2
DE14 Empty vector 60 0
Data are representative of at least two independent experiments. DE7 and
DE14 are two independent Cripto
 /  clones.T
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vide an intriguing link between Alk4/Smad pathway activa-
tion by Cripto and cardiomyocyte development.
Analysis of Cripto mutants identifies key residues both 
in the EGF and in the CFC domain
We showed above that the EGF-CFC domain is sufficient
to promote cardiogenic induction when overexpressed in
Cripto
 /  ES cells, whereas the EGF domain alone is un-
able to rescue the biological activity. To determine the con-
tribution of the EGF and CFC domains, single amino acid
substitutions were introduced into the cripto cDNA (Fig. 8
A), and the activity of the corresponding mutant proteins
was compared with the wt in the cardiomyocyte assay. Al-
though each mutant was expressed at levels comparable to
wt Cripto (Fig. 8 B), three of them were completely inactive
or showed a strongly reduced activity in our assay (Table
III). Similar results were obtained with two independent
Cripto
 /  ES clones (Table III). To support the observed
morphological data, the expression of the  MHC and the
MLC2v genes was examined by RT-PCR on total RNA pre-
pared from EBs derived from Cripto
 /  ES cells overex-
pressing Cripto mutant derivatives (Fig. 8 C). Expression of
 MHC and MLC2v genes was either absent or reduced in
cells overexpressing G71N, F78A, or W107G cripto mu-
tants, whereas it was restored in Cripto
 /  cells transfected
with wt cripto. Together these data show that critical amino
acid residues are located in both EGF and CFC domains,
thus indicating the requirement of both domains for Cripto
activity in cardiogenic induction.
Table II. Percentage of beating EBs from transfected Cripto
 /  
ES cells
Construct Protein EBs scored % of beating EBs
Alk4 ca None 50 16.0
Alk4 ca Cripto
a 87 87.3
Empty vector None 49 0
Empty vector Cripto
a 60 96.6
a2-d-old EBs were treated with 10  g/ml of recombinant Cripto for 3 d.
Figure 8. Identification of Cripto key residues required for cardiac induction and differentiation. (A) Schematic representation of wt and 
mutant Cripto derivatives. (B) Western blot analysis of total lysates from 293EBNA cells transfected with either wt or mutant cripto derivatives. 
Jun-HA expression vector was cotransfected as an internal control. Either polyclonal anti-Cripto or monoclonal anti-HA antibodies were used 
to detect protein levels. (C) RNA expression levels of the cardiac  MHC and MLC2v genes during in vitro differentiation of Cripto
 /  ES cells 
(days 5, 7, and 10) overexpressing either wt or mutant cripto derivatives. Expression level of HPRT gene was analyzed as an internal control.
Table III. Percentage of beating EBs from Cripto
 /  ES cells 
transfected with either wt or Cripto mutant derivatives
Cells Construct EBs scored % of beating EBs
DE7 None 97 0
DE7 Cripto wt 56 98.2
DE7 N63I 54 91.5
DE7 G71N 54 0
DE7 T72A 62 90.3
DE7 S77A 60 95.0
DE7 F78A 47 42.5
DE7 F78W 60 95.0
DE7 H104A 56 89.3
DE7 W107G 57 7.6
DE7 R116G 49 80.0
DE7 L122N 103 92.0
DE7 Empty vector 65 0
DE14 None 85 0
DE14 Cripto wt 54 94.4
DE14 G71N 49 0
DE14 F78A 45 66.0
DE14 W107G 57 30.5
DE14 Empty vector 71 0
Data are representative of at least two independent experiments. DE7 and
DE14 are two independent Cripto
 /  clones.T
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Recent reports have shown that Cripto is modified by
the addition of sugar residues. N-linked glycosylation was
shown to affect Cripto biological activity in the zebrafish as-
say (Minchiotti et al., 2001). More recently, an O-linked fu-
cosylation of Cripto has been reported to be required for
Cripto signaling activity in cotransfection assay in mamma-
lian cells (Schiffer et al., 2001; Yan et al., 2002). To assess if
posttranslational modifications were required for Cripto ac-
tivity in cardiogenic induction, two alanine substitutions
were generated, corresponding to either the N-glycosylation
site (N63I) or the O-linked fucosylation site (T72A). The
activities of the corresponding mutant proteins were tested
in the differentiation assay and compared with wt Cripto.
Based on the percentage of EBs containing beating areas,
both mutant proteins had comparable ability in promoting
cardiomyocyte differentiation, compared with wt Cripto
(Table III), thus suggesting that addition of sugar residues
was not strictly required for Cripto activity in ES cells.
However, a role of these modifications in the modulation
of Cripto signaling might be masked in our assay due to
overexpression of the proteins. To overcome this limitation,
we purified a recombinant Cripto T72A mutant protein
from conditioned medium of transfected 293 cells, and its
activity was compared with the wt Cripto. When used in the
cardiomyocyte differentiation assay, the Cripto T72A mu-
tant protein resulted in close to a 30% reduction in the
numbers of Cripto
 /  EBs displaying beating cardiomyo-
cytes, compared with the wt Cripto (Fig. 9). A similar reduc-
tion was observed when using Cripto T72A in the Smad2
phosphorylation assay, indicating that doses higher than
those used for wt Cripto were required to achieve equivalent
induction (unpublished data).
Nodal antagonists inhibit Cripto activity 
in cardiomyogenesis
To gain direct evidence that Nodal signaling is indeed re-
quired to support Cripto-regulated cardiac induction and
differentiation in ES cells, we sought to determine whether
inhibition of Nodal signaling might interfere with Cripto
ability to promote cardiomyogenesis. To directly address
this point, 2-d-old Cripto
 /  EBs were treated with in-
creasing amounts of recombinant Cripto (1–10  g/ml) in
a media containing the supernatant collected from a tran-
siently transfected 293T cell line producing Cerberus pro-
tein. This multifunctional antagonist inhibits Nodal as
well as BMP and Wnt signaling. However, a truncated
form of Cerberus, named Cerberus-Short (Cerberus-S), is a
specific Nodal antagonist (Piccolo et al., 1999). The pres-
ence of either Cerberus or Cerberus-S supernatant resulted
in a significant inhibition of Cripto ability to prime cardio-
myocyte differentiation compared with control superna-
tant (Fig. 10 A). Furthermore, we treated Cripto
 /  EBs
with 10  g/ml of recombinant Cripto in the presence of
increasing amounts of Cerberus-S–containing medium,
Figure 9. Modulation of Cripto activity by O-fucosylation. Dose-
dependent activity of T72A mutant Cripto compared with wt Cripto 
as assayed in cardiomyocyte differentiation assay. 2-d-old Cripto
 /  
EBs were treated with increasing amounts of either recombinant 
soluble T72A mutant or wt Cripto protein for 24 h and then cultured 
for the remaining days. Appearance of beating areas was scored from 
day 8 to 12 of the in vitro differentiation. Data are representative of 
two independent experiments.
Figure 10. Exposure to Cerberus inhibits Cripto activity in cardio-
myocyte differentiation assay. (A) Cerberus inhibits Cripto-dependent 
cardiomyocyte differentiation of Cripto
 /  EBs. 2-d-old Cripto
 /  EBs 
were cultured for 24 h in the presence of 100% (vol/vol) of media 
supernatant from 293T cells transiently expressing either Cerberus, 
Cerberus-S, or empty vector as control, in the presence of increasing 
amounts of recombinant Cripto protein. The number of Cripto
 /  
EBs containing beating areas was scored from day 8 to 12 of in vitro 
differentiation. Data are representative of two independent experi-
ments. (B) Inhibition of Cripto by Cerberus-S is dose dependent. 
2-d-old Cripto
 /  EBs were cultured for 24 h with 10  g/ml of soluble 
Cripto protein in the presence of increasing amounts (vol/vol) of 
media from 293T cells transiently expressing Cerberus-S. Cells were 
examined for cardiac differentiation as described above. Data are 
representative of two independent experiments.T
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thus being able to show that inhibition of Cripto activity
by Cerberus-S was indeed dose dependent (Fig. 10 B). Fi-
nally, as an additional control, we used Cripto
 /  ES cells
transfected with either Cerberus or Cerberus-S expression
vectors, before treatment of the derived EBs with recombi-
nant Cripto. In accord with the results obtained with con-
ditioned media, expression of either Cerberus or Cerberus-S
resulted in a significant inhibition of Cripto activity (Table
IV). Together, these results show that Cerberus and Cer-
berus-S can act as effective antagonists of Cripto signaling
in ES cell differentiation and provide evidence for a func-
tional role of the Nodal pathway in Cripto-mediated speci-
fication of the cardiac lineage.
Discussion
Role of secreted Cripto as a priming factor 
for cardiomyogenesis
Cripto is a GPI-anchored protein; however, recent data in
zebrafish have shown that Cripto protein could be pro-
vided in a soluble form to enable proper Nodal signal
propagation (Minchiotti et al., 2001). Moreover, previous
data on chimeric mouse embryos established from a com-
bination of wt and Cripto
 /  ES cells suggested that
Cripto acts nonautonomously during development (Xu et
al., 1998). Due to the absence of analysis of cellular genetic
markers, and because only late-stage chimeric embryos
were analyzed, the cell autonomous or nonautonomous ac-
tivity of Cripto is an issue that still remains unsolved
(Rosa, 2002). Expression of different deletion mutant
derivatives of cripto cDNAs in Cripto
 /  ES cells led us
to demonstrate that secreted Cripto could efficiently in-
duce cardiogenesis and, moreover, that expression of the
EGF-CFC domain was sufficient to restore the ability of
Cripto
 /  ES cells to differentiate into cardiomyocytes.
Furthermore, we showed that the Cripto EGF domain is
required, but not sufficient, for cardiomyogenesis. In con-
trast, it was previously demonstrated that a refolded syn-
thetic human Cripto peptide comprising only the EGF-
like domain displayed high affinity binding and mitogenic
activity on mammary cell lines (Salomon et al., 1999).
Considering the high percentage of amino acid identity
in the EGF domain between human and mouse Cripto
(Dono et al., 1993), this observation strengthened the hy-
pothesis that there may be divergent Cripto signaling path-
ways, depending both on different Cripto domains and on
specific cell types, that remain to be explored in the future.
Dose and temporal regulation of Cripto signaling in the 
commitment of ES cells to cardiac fate
EB differentiation is currently considered a powerful model
system, reproducing many aspects of in vivo tissue forma-
tion during the crucial, but less accessible, stages of mamma-
lian embryogenesis, thus providing access to early cell popu-
lations that develop in a normal fashion (Keller, 1995). The
timing of initiation of Cripto signaling and the strength and
duration of the signal are interdependent variables that have
not yet been resolved experimentally, mainly due to the
complexity of in vivo analysis. Western blot analysis per-
formed on total lysates, prepared at different times of ES cell
in vitro differentiation, showed a regulated accumulation of
Cripto protein whose expression was restricted to the very
beginning of the differentiation program.
We then used soluble Cripto protein on Cripto
 /  ES
cells to modulate Cripto signaling and measured its effect
on cardiomyocyte differentiation. Kinetic experiments per-
formed by adding recombinant Cripto protein directly to
the culture medium of Cripto
 /  ES cells demonstrated that
stimulation in trans with a soluble Cripto peptide was capa-
ble of promoting cardiac induction and, strikingly, revealed
an early acting window of time in which the initiation of
Cripto signaling is crucial for priming differentiation of ES
cells to cardiac fate. Having defined the timing of Cripto sig-
naling, we next examined two more variables, dose and du-
ration of signaling. Either different amounts of Cripto pro-
tein for a defined length of time or a high dose of Cripto
peptide for various lengths of time was used on Cripto
 / 
EBs. Both protein dose and signaling duration were crucial
parameters. Worth noticing, our results show that transient
presence of Cripto is inadequate and that sustained Cripto
signaling is strictly required to promote cardiogenesis. We
thus propose that Cripto activity at a given time, strength of
the signal, and length of the time of exposure are critical pa-
rameters for the correct specification and differentiation of
the cardiac lineage.
Neural cell fate is established from Cripto
 /  EB–derived 
cells in the absence of retinoic acid
Several studies demonstrated that neural differentiation from
ES cells relies upon an aggregation step followed by exposure
to specific inducing factors, such as retinoic acid (Bain et al.,
1995, 1996; Okabe et al., 1996). Our present findings indi-
cate that in the absence of retinoic acid, Cripto
 /  EB–
derived cells spontaneously differentiate into neurons. Fur-
thermore, we show that the timing of Cripto signaling
required for priming differentiation of cardiac cells resembles
the competence window of EB-derived cells to acquire a neu-
ral character. All together, our results indicate that Cripto sig-
naling is strictly required in an early acting window to nega-
tively regulate neural differentiation and, at the same time, to
permit differentiation of ES cells to cardiac fate.
Recent studies have investigated the mechanisms underly-
ing neural specification in uncommitted ES cells (Tropepe
et al., 2001). However, the role of the pathways that have
been implicated in neural generation in the context of stem
cells is still under investigation (Munoz-Sanjuan and Brivan-
lou, 2002). Although a better understanding of the molecu-
Table IV. Percentage of beating EBs from Cripto
 /  ES cells 
transfected with Nodal antagonists
Construct Protein EBs scored % of beating EBs
Empty vector None 40 0
Empty vector Cripto
a 58 85
Cerberus None 34 0
Cerberus Cripto
a 49 10.3
Cerberus-S None 36 0
Cerberus-S Cripto
a 40 8.3
a2-d-old EBs were treated with 10  g/ml of recombinant Cripto for 3 d.T
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lar events that mediate the acquisition of neural fates of ES
cells in the absence of Cripto signaling is required, our con-
trolled differentiation paradigm could represent an attractive
system to further investigate this issue.
Cripto signaling pathway in cardiomyogenesis
Both genetic and biochemical data indicate a role for Cripto
and, more generally, for the EGF-CFC factors in Nodal sig-
naling (Gritsman et al., 1999; Reissmann et al., 2001;
Schiffer et al., 2001; Yan et al., 2002). More recently, find-
ings in Xenopus and zebrafish have also shown that the
TGF  Vg1/GDF1-like signals depend on EGF-CFC pro-
teins (Cheng et al., 2003).
We observed a significant increase in Smad2 phosphory-
lation consequent to treatment of Cripto
 /  ES cells with
recombinant Cripto protein for different lengths of time.
This suggests that Cripto signaling acts through the Smad2
pathway to promote cardiac induction and reveals a poten-
tial role of Nodal signaling in cardiogenesis. Acute stimula-
tion by Cripto, although competent in activating Smad2, is
insufficient to achieve proper terminal cardiac differentia-
tion, again highlighting the importance of signal duration
for cardiomyogenesis.
Activation of Alk4/Tar-A signaling and cardiac induction
One critical function of Cripto during development is to
render Activin type I receptor competent for activation by
Nodal and to potentiate Nodal-triggered Alk7 signaling ac-
tivity (Gritsman et al., 1999; Reissmann et al., 2001; Yeo
and Whitman, 2001; Yan et al., 2002). Here we show that
activated forms of either Alk4 or zebrafish Taram-A partially
compensate for the lack of Cripto in the cardiomyocyte dif-
ferentiation assay, suggesting that, indeed, this receptor fam-
ily is involved in Cripto-mediated cardiomyogenesis. The
incomplete rescue could be due to different reasons. As over-
expression experiments do not allow the modulation of re-
ceptor signaling both in terms of timing and signal strength,
we measured the effect of constitutive, but not transient
(acute), activation of Alk4-mediated signaling. Cripto may
also interact either with other Alk or TGF  receptor family
members or still unknown molecules to promote cardio-
myocyte induction and differentiation in ES cells.
Mutational dissection of Cripto
The mutational dissection of Cripto enabled us to define
that both the EGF and the CFC domains are crucial for
Cripto activity in cardiogenesis. Remarkably, the biological
activities of the Cripto mutants in cardiogenic induction cor-
relate well with their effects on Alk4/Nodal signaling. First,
the two amino acids located in the EGF domain whose mu-
tation significantly reduces or completely abolishes Cripto
activity, namely G71 and F78, also appeared to be strictly re-
quired to rescue cell competence to respond to Nodal signal-
ing in the zebrafish assay (Minchiotti et al., 2001). Interest-
ingly, the impaired activity of mutant Cripto protein was
dependent on the amino acids chosen for the substitution. In
fact, while substitution of phenylalanine to alanine (F78A)
significantly reduced protein activity, a tryptophan in the
same position (F78W) preserved Cripto ability to promote
cardiogenesis. Worth noting, F78 is fully exposed in the 3D
model of Cripto and has been hypothesized to be involved in
protein binding (Lohmeyer et al., 1997; Minchiotti et al.,
2001). Second, receptor reconstitution experiments in Xeno-
pus have indicated that the EGF domain of Cripto is crucial
for Nodal binding to the Alk4/ActRIIB receptor complex
(Yeo and Whitman, 2001), while the CFC domain was re-
quired for Cripto to interact with the Alk4 receptor. Specifi-
cally, either double or triple mutations in the CFC domain,
including the amino acid W107, have been reported to im-
pair Alk4-dependent Cripto activity (Yeo and Whitman,
2001; Yan et al., 2002). Here, we show that the single amino
acid substitution of residue W107 in the CFC domain se-
verely impairs the ability of Cripto to promote cardiac induc-
tion in Cripto
 /  ES cells. Finally, several reports have de-
scribed the modification of Cripto by the addition of sugar
residues, including a rare case of fucosylation, suggesting that
the activity of Cripto may be controlled by the extent of its
glycosylation or fucosylation (for review see Rosa, 2002).
Here we show that an alanine substitution in the site of
O-fucosylation (T72A; Yan et al., 2002) generates a Cripto
mutant protein that is still competent to promote cardio-
myocyte differentiation, although showing a reduced activity
compared with the wt. Although T72A modification of
Cripto has been previously shown to be completely inactive
in facilitating Nodal signaling in Xenopus (Schiffer et al.,
2001) and in coculture assay (Yan et al., 2002), recent data
showed that mutant embryos lacking O-fucosyltransferase do
not resemble the cripto knockout phenotype, thus suggesting
a less stringent requirement for O-fucose on Cripto activity
in vivo than in reporter assay (Shi and Stanley, 2003).
Nodal signaling is required for Cripto-regulated 
cardiomyogenesis
Results reported herein suggested that Nodal signaling was re-
quired for Cripto-regulated cardiac induction and differentia-
tion. To obtain more direct evidence to support this hypoth-
esis, we performed loss-of-function experiments by using
Nodal antagonists in our controlled differentiation assay. To
this end, either Cerberus or Cerberus-S proteins were used, ei-
ther by transfecting Cripto
 /  ES cells with corresponding ex-
pression vectors or by using conditioned media containing the
recombinant proteins. In both cases, the presence of either
Cerberus or Cerberus-S results in a strong inhibition of Cripto
activity in the differentiation assay, thus supporting the idea
that Nodal is indeed required to mediate Cripto-dependent
cardiomyocyte induction and differentiation of ES cells.
Understanding the early events of lineage segregation dur-
ing differentiation of mammalian cells is crucial for the pros-
pects of controlling stem cell differentiation for biomedical
application. Although ES cells represent a viable source of
donor cells for transplantation and gene delivery, the suc-
cessful use of ES-derived donor cells would require the gen-
eration of essentially pure cultures of specific cell types (Bo-
heler et al., 2002). In this respect, our results open new
insights into the understanding of the molecular mecha-
nisms by which cripto regulates cardiogenesis, and will hope-
fully contribute to the characterization of the molecular sig-
nals that control both cardiac and neuronal differentiation
of stem cells as the first step in the ongoing efforts to employ
these cells in regenerative medicine.T
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Materials and methods
Plasmids and mutants
The pallino  A vector was derived from the pallino vector (provided by S.
Chiocca, European Institute of Oncology, Milan, Italy) by replacing the
CMV promoter with the chicken  -actin promoter (pCXN2 vector; Niwa et
al., 1991). Restriction sites were blunt ended using Klenow polymerase.
All the cripto mutant derivatives were obtained as previously described
(Minchiotti et al., 2001). The Cripto-His here renamed “secreted Cripto”
and the EGF-CFC derivatives have been previously described (Minchiotti
et al., 2001). The cripto EGF long (nucleotide  5 to  288 of cripto cDNA;
Dono et al., 1993), cripto EGF short (nucleotide  5 to  75 fused to  157/
 288 of cripto cDNA), wt and activated (ca) Alk4, wt and activated (ca)
Taram-A, Cerberus, and Cerberus-S cDNAs were all subcloned into pal-
lino  A vector.
Cell cultures and ES differentiation
Human embryonic kidney 293 and 293EBNA cells and undifferentiated ES
cells were cultured as previously described (Xu et al., 1999; Minchiotti et
al., 2001). For in vitro differentiation, ES cells were cultivated in EBs essen-
tially as previously described (Wobus et al., 1991; Maltsev et al., 1993;
Fig. 1). The EBs were plated separately onto gelatin-coated 48-well plates
for morphological analysis or onto 100-mm tissue culture plates for RT-
PCR and Western blot.
Cell transfections and proteins
Undifferentiated ES cells (10
7/ml) were electroporated with linearized
DNA (30  g) at 400 V, 250  F. 1 wk after selection with 2  g/ml puromy-
cin, resistant clones were pooled, expanded, and subjected to the differen-
tiation assay. Transfection of 293EBNA cells was performed as previously
described (Minchiotti et al., 2000).
Recombinant secreted Cripto proteins were obtained and purified as
previously described (Minchiotti et al., 2001). Conditioned media contain-
ing either Cerberus or Cerberus-S were obtained from 293T cells as previ-
ously described (Piccolo et al., 1999).
Western blotting
Either undifferentiated ES cells or EBs were lysed either in a buffer contain-
ing 10 mM Tris/Cl, pH 8, 140 mM NaCl, 2 mM EDTA, pH 8, 1% NP-40 or
dissolved in Laemmli lysis buffer (Laemmli, 1970) and analyzed by West-
ern blot using the Trans-Blot Semi-dry System (Bio-Rad Laboratories). The
anti-HA (12CA5) antibody (ROCHE), anti-Porin 31HL antibody (Calbio-
chem), anti-Smad2/3, and anti–phospho-Smad2 (Ser465/467) (Upstate
Biotechnology) were used according to the manufacturer’s instructions.
RNA preparation and RT-PCR
Total RNA from either undifferentiated ES cells or EBs was extracted with
TRIzol kit (Life Technologies) according to the manufacturer’s instructions
and reverse transcribed to cDNA with SuperScript II reverse transcriptase
(Life Technologies) and random hexamers (as primers). cDNA samples syn-
thesized from 100 ng of total RNA were subjected to PCR amplification
with specific primers. The primers and the PCR conditions used were as
follows: Nodal, 5 -TTCCTTCTCAGGTCACGTTTGC-3  (forward) and 5 -
GGTGGGGTTGGTATCGTTTCA-3  (reverse), annealing temperature 58 C,
cycles 35, producing a 518-bp fragment; ALK-4, 5 -AAGGATCCAG-
GCTCTGCTGTGTGCC-3  (forward) and 5 -ACGGATCCATGTCCAAC-
CTCTGGCGG-3  (reverse), annealing temperature 60 C, cycles 30, 411-bp
fragment; ActRIIB, 5 -ATGTGCCGTGGTGTCGTGGT-3  (forward) and 5 -
GACCTCCTGATCAGGGATAC-3  (reverse), annealing temperature 58 C,
cycles 30, 54-bp fragment; MLC2v, 5 -GCCAAGAAGCGGATAGAAG-
GCGGG-3  (forward) and 5 -CTGTGGTTCAGGGCTCAGTCCTTC-3  (re-
verse), annealing temperature 70 C, cycles 33, 490-bp fragment; cardiac
 MHC, 5 -GGAAGAGTGAGCGGCGCATCAAGG-3  (forward) and 5 -CTG-
CTGGAGAGGTTATTCCTCG-3  (reverse), annealing temperature 65 C,
cycles 30, 301-bp fragment. A set of primers for hypoxanthine phosphori-
bosyltransferase (HPRT), 5 -CCTGCTGGATTACATTAAAGCACTG-3  (for-
ward) and 5 -CCTGAAGTACTCATTATAGTCAAGG-3  (reverse), anneal-
ing temperature 58 C, cycles 25, 369-bp fragment, was used as a control.
Immunofluorescence of EBs
Adherent EBs were fixed either in methanol/acetone (7:3; MF-20 antibody)
or in 4% paraformaldehyde in PBS ( -tubulin isotype III). EBs were treated
with 0.1% Triton X-100 (Sigma-Aldrich), 10% normal goat serum (Dako-
Cytomation) in PBS and incubated with primary antibodies in 10% NGS,
1  PBS at the following working dilutions: anti–neurofilament-M (1:400;
Chemicon International), anti– -tubulin isotype III (1:400; Sigma-Aldrich),
and anti–sarcomeric myosin (MF-20, 1:50; monoclonal supernatant ob-
tained from the Developmental Studies Hybridoma Bank, University of
Iowa). After washing, EBs were incubated with secondary antibodies, ei-
ther fluorescein (Boehringer) or rhodamine conjugated (Jackson Immu-
noResearch Laboratories), in 10% NGS, 1  PBS. After PBS wash, EBs were
counterstained with DAPI and mounted in Vecta Shield medium (Vector
Laboratories). Labeling was visualized by epifluorescent illumination using
an Axioskop 2 microscope, and images were acquired on an Axiocam
ARC camera (Carl Zeiss MicroImaging, Inc.).
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